

# Zogenix Inc (ZGNX) - Financial and Strategic SWOT Analysis Review

<https://marketpublishers.com/r/ZA3DE31E13DEN.html>

Date: May 2021

Pages: 55

Price: US\$ 125.00 (Single User License)

ID: ZA3DE31E13DEN

## Abstracts

Zogenix Inc (ZGNX) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company's businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company's key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

The profile contains critical company information including:

Business description – A detailed description of the company's operations and business divisions.

Corporate strategy – Analyst's summarization of the company's business strategy.

SWOT Analysis – A detailed analysis of the company's strengths, weakness, opportunities and threats.

Company history – Progression of key events associated with the company.

Major products and services – A list of major products, services and brands of the company.

Key competitors – A list of key competitors to the company.

Key employees – A list of the key executives of the company.

Executive biographies – A brief summary of the executives' employment history.

Key operational heads – A list of personnel heading key departments/functions.

Important locations and subsidiaries – A list and contact details of key locations and subsidiaries of the company.

Detailed financial ratios for the past five years – The latest financial ratios derived from the annual financial statements published by the company with 5 years history.

Interim ratios for the last five interim periods – The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.

## Highlights

Zogenix Inc (Zogenix) develops and markets therapies for the treatment of patients with rare diseases. The company's marketed product include Fintepla (fenfluramine) approved in the US, the UK and EU for the treatment of dravet syndrome. Its pipeline product candidate include MT1621, an investigational deoxynucleoside combination therapy for the treatment of thymidine kinase 2 deficiency (TK2d); Fintepla for Lennox-Gastaut syndrome (LGS) and other rare epilepsies; and gene therapies for dravet syndrome and other epilepsy disorders. The company through its subsidiaries operates in the US, the UK, Germany, Ireland, Japan, France and Italy. Zogenix is headquartered in Emeryville, California, the US.

### Zogenix Inc Key Recent Developments

May 06,2021: Zogenix provides corporate update and reports first quarter 2021 financial results

Mar 02,2021: Zogenix to Participate in the Raymond James Institutional Investors Conference

Feb 18,2021: Zogenix to Participate in the 10th Annual SVB Leerink Global Healthcare Conference

Feb 11,2021: Zogenix to Release Fourth Quarter and Full-Year 2020 Financial Results

and Host Conference Call and Webcast on February 25

Jan 11,2021: Zogenix announces preliminary, unaudited fourth quarter 2020 net product sales

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.

The profile analyzes the company's business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.

Understand and respond to your competitors' business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.

The company's core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.

Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.

Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.

Scout for potential investments and acquisition targets, with detailed insight into the companies' strategic, financial and operational performance.

Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.

Gain key insights into the company for academic or business research.

Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.

**Note:** Some sections may be missing if data is unavailable for the company

## Contents

### **SECTION 1 - ABOUT THE COMPANY**

Zogenix Inc - Key Facts  
Zogenix Inc - Key Employees  
Zogenix Inc - Key Employee Biographies  
Zogenix Inc - Major Products and Services  
Zogenix Inc - History  
Zogenix Inc - Company Statement  
Zogenix Inc - Locations And Subsidiaries  
Head Office  
Other Locations & Subsidiaries

### **SECTION 2 – COMPANY ANALYSIS**

Company Overview  
Zogenix Inc - Business Description  
Other Break-up: Collaboration Revenue  
Performance  
Other Break-up: Net Product Sales  
Performance  
R&D Overview  
Zogenix Inc - Corporate Strategy  
Zogenix Inc - SWOT Analysis  
SWOT Analysis - Overview  
Zogenix Inc - Strengths  
Zogenix Inc - Weaknesses  
Zogenix Inc - Opportunities  
Zogenix Inc - Threats  
Zogenix Inc - Key Competitors

### **SECTION 3 – COMPANY FINANCIAL RATIOS**

Financial Ratios - Capital Market Ratios  
Financial Ratios - Annual Ratios  
Performance Chart  
Financial Performance  
Financial Ratios - Interim Ratios

Financial Ratios - Ratio Charts

## **SECTION 4 – COMPANY’S LIFESCIENCES FINANCIAL DEALS AND ALLIANCES**

Zogenix Inc, Pharmaceuticals & Healthcare, Deals By Year, 2015 to YTD 2021

Zogenix Inc, Pharmaceuticals & Healthcare, Deals By Type, 2015 to YTD 2021

Zogenix Inc, Recent Deals Summary

## **SECTION 5 – COMPANY’S RECENT DEVELOPMENTS**

May 06, 2021: Zogenix provides corporate update and reports first quarter 2021 financial results

Mar 02, 2021: Zogenix to Participate in the Raymond James Institutional Investors Conference

Feb 18, 2021: Zogenix to Participate in the 10th Annual SVB Leerink Global Healthcare Conference

Feb 11, 2021: Zogenix to Release Fourth Quarter and Full-Year 2020 Financial Results and Host Conference Call and Webcast on February

Jan 11, 2021: Zogenix announces preliminary, unaudited fourth quarter 2020 net product sales

Sep 21, 2020: Zogenix appoints three industry leaders to its Board of Directors

Aug 05, 2020: Zogenix provides corporate update and reports second quarter 2020 financial results

Jun 12, 2020: Zogenix introduces new resources for Dravet Syndrome siblings

May 05, 2020: Zogenix provides corporate update and reports first quarter 2020 financial results

Apr 20, 2020: Zogenix appoints Shawnte Mitchell as Executive Vice President, General Counsel & Secretary

## **SECTION 6 – APPENDIX**

Methodology

Ratio Definitions

About GlobalData

Contact Us

Disclaimer

## List Of Tables

### LIST OF TABLES

Zogenix Inc, Key Facts  
Zogenix Inc, Key Employees  
Zogenix Inc, Key Employee Biographies  
Zogenix Inc, Major Products and Services  
Zogenix Inc, History  
Zogenix Inc, Subsidiaries  
Zogenix Inc, Key Competitors  
Zogenix Inc, Ratios based on current share price  
Zogenix Inc, Annual Ratios  
Zogenix Inc, Annual Ratios (Cont...1)  
Zogenix Inc, Interim Ratios  
Zogenix Inc, Pharmaceuticals & Healthcare, Deals By Year, 2015 to YTD 2021  
Zogenix Inc, Pharmaceuticals & Healthcare, Deals By Type, 2015 to YTD 2021  
Zogenix Inc, Recent Deals Summary  
Currency Codes  
Capital Market Ratios  
Equity Ratios  
Profitability Ratios  
Cost Ratios  
Liquidity Ratios  
Leverage Ratios  
Efficiency Ratios

## List Of Figures

### LIST OF FIGURES

Zogenix Inc, Performance Chart (2016 - 2020)

Zogenix Inc, Ratio Charts

Zogenix Inc, Pharmaceuticals & Healthcare, Deals By Year, 2015 to YTD 2021

Zogenix Inc, Pharmaceuticals & Healthcare, Deals by Type, 2015 to YTD 2021



## I would like to order

Product name: Zogenix Inc (ZGNX) - Financial and Strategic SWOT Analysis Review

Product link: <https://marketpublishers.com/r/ZA3DE31E13DEN.html>

Price: US\$ 125.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

[info@marketpublishers.com](mailto:info@marketpublishers.com)

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/ZA3DE31E13DEN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:  
Last name:  
Email:  
Company:  
Address:  
City:  
Zip code:  
Country:  
Tel:  
Fax:  
Your message:

**\*\*All fields are required**

Customer signature \_\_\_\_\_

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970